This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in achieving greater reductions in both body weight and waist circumference. While both medications led to similar rates of overall adverse events, predominantly gastrointestinal, tirzepatide resulted in a higher percentage of participants reaching significant weight loss targets.
Audio Overview (Google NotebookLM)
(17 minutes 14 seconds)
